Notice of Filing Securities Class Action Against Immucor, Inc.

SAN DIEGO--(Business Wire)--
Coughlin Stoia Geller Rudman & Robbins LLP ("Coughlin Stoia")
(http://www.csgrr.com/cases/immucorinc/) today announced that a class action has
been commenced on behalf of an institutional investor in the United States
District Court for the Northern District of Georgia on behalf of purchasers of
Immucor, Inc. ("Immucor") (NASDAQ:BLUD) publicly traded securities during the
period between October 19, 2005 and April 23, 2009 (the "Class Period").

If you wish to serve as lead plaintiff, you must move the Court no later than 60
days from today. If you wish to discuss this action or have any questions
concerning this notice or your rights or interests, please contact plaintiff`s
counsel, Darren Robbins of Coughlin Stoia at 800/449-4900 or 619/231-1058, or
via e-mail at djr@csgrr.com. If you are a member of this class, you can view a
copy of the complaint as filed or join this class action online at
http://www.csgrr.com/cases/immucorinc/. Any member of the putative class may
move the Court to serve as lead plaintiff through counsel of their choice, or
may choose to do nothing and remain an absent class member.

The complaint charges Immucor and certain of its officers and directors with
violations of the Securities Exchange Act of 1934. Immucor develops,
manufactures and sells a complete line of reagents and automated systems used
primarily by hospitals, clinical laboratories and blood banks in a number of
tests performed to detect and identify certain properties of the cell and serum
components of human blood prior to blood transfusion.

The complaint alleges that during the Class Period, defendants materially
misrepresented the Company`s business operations. Specifically, defendants
failed to disclose that Immucor was operating in violation of the federal
antitrust laws of the United States.

The complaint further alleges that on April 24, 2009, the Company issued a press
release, which stated in part: "Immucor, Inc., a global leader in providing
automated instrument-reagent systems to the blood transfusion industry, today
announced that it received a subpoena from the United States Department of
Justice, Antitrust Division, requesting documents for the period beginning
September 1, 2000 through the present, pertaining to an investigation of
possible violations of the federal criminal antitrust laws in the blood reagents
industry. Immucor intends to fully cooperate with the investigation."

As a result of this disclosure, Immucor`s closing stock price dropped from
$20.98 on April 23, 2009 to $15.35 the next trading day. This decrease in
Immucor`s stock price was a result of the artificial inflation caused by
defendants` misleading statements coming out of the stock price.

Plaintiff seeks to recover damages on behalf of all purchasers of Immucor
publicly traded securities during the Class Period (the "Class"). The plaintiff
is represented by Coughlin Stoia, which has extensive experience in prosecuting
investor class actions and actions involving financial fraud.

Coughlin Stoia Geller Rudman & Robbins LLP
Darren J. Robbins, 800-449-4900
djr@csgrr.com

Copyright Business Wire 2009